Skip to main content
SpringerLink
Log in

Acomplia ADRs reported to MHRA

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. The Medicines and Healthcare Products Regulatory Agency, Commission on Human Medicines (CHM).Rimonabant (Acomplia): depression; psychiatric adverse reactions. Drug Safety Update 1: 2-4, No. 10, May 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acomplia ADRs reported to MHRA. React. Wkly. 1202, 2 (2008). https://doi.org/10.2165/00128415-200812020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812020-00003

Keywords

Search

Navigation